Aixia Ma
1PUBLICATIONS
0CO-AUTHORS

Get your video featured.

Get your video featured.
Publications (1)
Sort by Publication Date:
|Nov 05, 2022
Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China.Zhengyang Fei, Mingjun Rui, Yingcheng Wang
Pageof 1
